News Sanofi/Regeneron asthma trial casts doubt on IL-33 class prospects Phil Taylor AnaptysBio, asthma, Dupixent, Regeneron, Sanofi, severe asthma 0 Comment The good news for Sanofi and Regeneron is that their interleukin-33-targeting drug seems to work in asthma. The Share X Sanofi/Regeneron asthma trial casts doubt on IL-33 class prospects https://pharmaphorum.com/news/sanofi-regeneron-asthma-trial-casts-doubt-il-33-class-prospects/
AnaptysBio, asthma, Dupixent, Regeneron, Sanofi, severe asthma
0 Comment
